Annovis Raises $21M to Fund Pivotal Alzheimer’s Trial Readout

Annovis Bio

MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) raised $21 million in a November stock offering to finance operations through a pivotal Alzheimer’s disease clinical trial readout scheduled for March 2027, securing additional capital after its cash reserves fell to $2.8 million at the end of September.

The Malvern-based biotechnology company closed the underwritten public offering November 6, with its board chairman contributing $5 million. Management expects the proceeds to support operations through the six-month results from DUET-AD, its Phase 3 trial evaluating the experimental oral treatment buntanetap.

Annovis reported cash and cash equivalents of $2.8 million as of September 30, down from $19.5 million at the end of 2025, reflecting spending as the company advanced its clinical development programs.

Research and development expenses increased to $15.8 million in the third quarter from $6.3 million a year earlier. General and administrative expenses rose to $1.2 million from $1.1 million.

READ:  TELA Bio Revenue Falls 8% as Company Cuts Costs

The company reported a net loss of $0.22 per share, compared with a loss of $0.37 per share in the third quarter of 2025. Annovis had approximately 42.7 million common shares outstanding at September 30.

The financing comes as Annovis approaches its first major efficacy assessment in DUET-AD, which has completed enrollment of 862 patients with early Alzheimer’s disease who tested positive for the blood biomarker pTau217.

The company expects the final patient visit for the six-month treatment assessment on December 31, followed by a database lock February 8 and topline results in March 2027.

The six-month analysis will evaluate symptomatic effects. Patients will continue treatment for another 12 months to complete a separate, prespecified 18-month assessment of potential disease-modifying effects.

READ:  Century Therapeutics Cuts Loss as Cell Therapies Near Trials

“The third quarter marked a shift in our focus from enrolling patients in DUET-AD to executing the trial and preparing for the first data readout and for filing a New Drug Application (NDA),” said Maria Maccecchini, Annovis’ president and chief executive officer.

Annovis is preparing a potential regulatory submission to the Food and Drug Administration and entered a partnership with Weave Bio in September to use artificial intelligence-based tools for regulatory documentation and information management.

The company intends to complete a substantial portion of its planned New Drug Application before the March trial results become available.

Annovis is also preparing an open-label extension of DUET-AD that will allow eligible participants from both the treatment and placebo groups to receive buntanetap after completing the 18-month study. Participants from earlier Alzheimer’s trials may also enroll.

READ:  ArriVent Posts $133.5 Million Loss as Cancer Trial Falls Short

Patient transfers into the extension study are expected to begin by the end of November.

Separately, the company’s Parkinson’s disease open-label extension study has enrolled 326 patients, with enrollment scheduled to close January 29, 2027.

The 36-month study is evaluating the long-term safety and efficacy of buntanetap in participants from previous clinical trials and new patients who have undergone deep brain stimulation.

Researchers are using NeuroRPM, a digital measurement system for Parkinson’s symptoms, alongside skin biopsy testing for alpha-synuclein pathology.

Annovis plans to present the six-month DUET-AD findings at the 2027 International Conference on Alzheimer’s and Parkinson’s Diseases in Barcelona.

Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.